Insider trade

Officer sold ~$810K of VTRS shares in the open market

Traded Jun 25, 2026 · Filed Jun 26, 2026

ViatrisVTRS

~$810K
Reported value · 50K sh @ $16.1711: 316K
Holds after · shares reported: +8.7%
stock since the trade · S&P 500 +4.0%, $16.07 → $17.46 on Oct 1

Why it stands out

Viatris's See Remarks sold $810K of Viatris shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jun 25, 2026
Reporting period: Not applicable
Filed with the SEC: Jun 26, 2026

Officer$500K–$1MPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$809,784

Shares × reported transaction price

Timing vs results

49 days after results of May 7, 2026, 42 days before results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $16.07 on Jun 25, 2026, 84% above its 52-week low and 8% below its high, after a 6% drop over the previous 30 trading days

52-week range $8.74 (Jul 31, 2025) to $17.39 (May 7, 2026), 85% of the way up, from 251 adjusted closes. 30 trading days earlier: $17.17 on May 12, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Ferric Carboxymaltose on Jun 25, 2026, the same day as this trade.

Generic drug approved. Active ingredient: Ferric Carboxymaltose. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+3.5%	+1.4%	+2.1%
30 days	+9.8%	-1.6%	+11.4%
90 days	+12.6%	+3.3%	+9.3%

Past results only. Not a forecast.

Source receipt

Record ID: 0001140361-26-026593
Filed / recorded: Jun 26, 2026, 9:00 PM UTC
Added to OQRO: Oct 2, 2026, 12:29 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Viatris Inc
Issuer CIK: 1792044
Ticker: VTRS
Reporting person: Paul Campbell
Relationship: Officer
Officer title: See Remarks
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jun 25, 2026
Transaction code: S
Shares / units: 50,076
Price per share: $16.1711
Acquired / disposed: Disposed (D)
Shares owned after: 316,212
Ownership form: Direct
Amendment: No

Footnotes from the filing

These shares of common stock were sold pursuant to a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, that was adopted by the reporting person on March 24, 2026.
Represents the weighted average price of the reporting person's disposition of 50,076 shares of common stock in transactions ranging from $15.979 to $16.31. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote.

Around the same time

3mo ago

2,362Derivative units · @ $15.88

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

3mo ago

2,756Derivative units · @ $15.88

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

6mo ago

39KShares

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record